Xerosis
Conditions
Brief summary
In the general population, xerosis is often caused by external factors such as seasonal changes. In that case, the best way to relieve dry skin is to use a standard moisturizer. However, for those suffering of mobility problems due to age or paralysis (e.g., spinal cord injury, multiple sclerosis, Parkinson's, etc), xerosis is often severe and chronic because of the multiple causes (endogenous rather than exogenous ones) underlying such mobility impairment-related skin problems. This study is a double-blind, randomized study with positive control (active comparator) to assess the safety and efficacy of SQIN with CanSATs (Co-Activation of Natural Synergistically Acting Target-receptorS) technology on dry skin in patients suffering of paralysis.
Detailed description
Xerosis is a medical term for dry skin. When it results in skin that is scaly and itchy, the condition is called pruritus. This occurs when natural moisture is drawn out of the skin. The skin needs moisture to protect itself. The best way to relieve dry skin normally, for those suffering of seasonal dry skin problems, is to use standard moisturizers. However, for those suffering of mobility problems due to age or paralysis (spinal cord injury, multiple sclerosis, Parkinson's, Alzheimer's, muscular dystrophy, amputation, cerebral palsy, or other comparable disorders), xerosis becomes severe and chronic because of the multiple causes (endogenous metabolic problems and dysfunctions rather than exogenous ones). SQIN with CanSATs technology is designed to act upon multiple mechanisms for enhanced protecting, moisturizing, and repairing effects. Based upon preliminary evidence, SQIN with CanSATs technology can thus elicit significantly superior effects compared with standard, commercially available moisturizers.
Interventions
OTHERSQIN
Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
OTHERstandard moisturizing cream (Glaxal Base)
Sponsors
Nordic Life Science Pipeline Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Paralyzed due to a spinal cord injury (traumatic or non-traumatic origin) * Chronically injured (at least 3 months post-injury) * Paraplegic or tetraplegic * 18-75 years of age * Men and women * French-speaking
Exclusion criteria
* Acute or subacute stage (within 1 day and 3 months post-injury) * Had tumor(s) (malignant or non-malignant) of the skin in the last five (5) years * Allergic or hypersensitive to any ingredient, investigational or control product * With psychiatric or mental disorder(s) * Children (younger than 18 year-old) or elderly (older than 75 year-old) * Not French-speaking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Skin tolerance (Self-assessment of redness or itchiness problems) | 14 days | Self-assessment of redness or itchiness problems during or after the treatment |
| Moisturizing level (Self-assessment (5-level score) | 14 days | Self-assessment (5-level score) of dry skin conditions before, during and after the treatment |
| Elasticity level (Self-assessment (5-level score) | 14 days | Self-assessment (5-level score) of the elasticity level of the skin before, during and after the treatment |
Countries
Canada
Outcome results
None listed